ArticleCell biochemistry and biophysics2026
Cardio Protective Role of Graphene-based Fe
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present investigation is aiming to explore the cardioprotective implications of Graphene-based Fe2O3 nanozymes and Fe2O3 nanoparticles against isoproterenol (ISO)-instigated myocardial infarction (MI) in rats. Fe2O3 nanoparticles were prepared through green synthesis method using the plant extract of Trigonella foenum-graecum, and graphene was synthesized by the modified hammer method. However, Fe₂O₃-graphene nanozymes were fabricated using ultrasonication method. Oxidative stress, cardiac injury and inflammation were assessed via biochemical markers including cardiac indicators (Troponin I, creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH)), antioxidative assembly (superoxide dismutase (SOD), glutathione (GSH) and catalase (CAT)), inflammatory markers (IL-1β, IL-6 and TNF-α), apoptotic related proteins (BaX and Bcl-2) lipid profile, hematological and hepatological parameters. Histopathological changes in myocardium were assessed via hematoxylin and eosin (H&E) staining. Graphene-based Fe₂O₃ nanozymes significantly cast a restorative influence on ISO-induced cardiac damage by enhancing the levels of SOD (p < 0.01 **), GSH (p < 0.01 **) and CAT enzymes accompanied by significant reduction in levels of cardiac biomarkers (LDH, CK-MB and Troponin I) and lipid content in blood serum (p < 0.001 ***). Likewise, normal restoration level of hematological, inflammatory and molecular markers was also observed with significance level of (p < 0.001 ***). Histological observations confirmed reduced myocardial damage and inflammation in the treated group. As compared to the Fe₂O₃ nanoparticles, graphene-based Fe₂O₃ nanozymes exhibited greater protective efficacy, highlighting their potential in mitigating ISO-induced oxidative stress and inflammation. These findings suggest that graphene-based Fe₂O₃ nanozymes are promising candidates for cardio protection in myocardial injury models.
Indexed as
Identifiers
41530442What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.